Publication

Application

Priority

DE 19708713 A 19970304

EP 9801089 W 19980226

Abstract (en)

[origin: DE19708713A1] The present invention relates to the use of anti-CD44 antibodies from the constant portion (sDC44) and variable portion of CD44 (VCD44) in the treatment of certain tumours and other diseases which are associated with degeneracy and activation of Langerhans cells (LC) and dendritic cells (DC) in the body of a mammal including human beings, and in the treatment of undesirable immune reactions. The invention also relates to an ex vivo culture method for the production of dendritic cells.